AstraZeneca today announced the successful completion of the acquisition of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), 一家全球临床阶段澳门第一赌城在线娱乐公司，开发用于治疗癌症和自身免疫性疾病的创新细胞疗法, furthering AstraZeneca’s cell therapy ambition.
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F, a novel, 临床阶段的BCMA和CD19双靶向自体嵌合抗原受体t细胞(CAR-T)治疗. GC012F is a potential new treatment for multiple myeloma, 以及其他血液恶性肿瘤和自身免疫性疾病，包括系统性红斑狼疮(SLE).
Gracell will operate as a wholly owned subsidiary of AstraZeneca, with operations in China and the US.
Financial considerations
Under the terms of the definitive agreement, 澳门在线赌城娱乐通过合并以2美元的价格收购了Gracell的全部稀释股本(包括ads代表的股份).00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell) plus a non-tradable contingent value right of $0.30 per ordinary share (equivalent to $1.在达到规定的监管里程碑后支付现金(每股Gracell ADS 50美元).
对价的预付现金部分代表约1美元的交易价值.0bn. Combined, the upfront and potential contingent value payments represent, if achieved, a transaction value of approximately $1.2bn.
Notes
About GC012F
GC012F is Gracell’s FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, 它的目标是通过寻求驱动深度和持久的反应并提高安全性来改变癌症和自身免疫性疾病的治疗. GC012F目前正在多种血液恶性肿瘤和自身免疫性疾病的临床研究中进行评估. Gracell已经在美国启动了一项评估GC012F治疗复发或难治性多发性骨髓瘤的Ib/II期试验.
AstraZeneca in haematology
AstraZeneca is pushing the boundaries of science to redefine care in haematology. We have expanded our commitment to patients with haematologic conditions, not only in oncology but also in rare diseases with the acquisition of Alexion, allowing us to reach more patients with high unmet needs. By applying our deep understanding of blood cancers, 利用澳门第一赌城在线娱乐在实体肿瘤肿瘤学方面的优势，并秉承Alexion在补体科学方面的开创性传统，为罕见疾病提供创新药物, 澳门第一赌城在线娱乐正在追求针对疾病潜在驱动因素的新疗法的端到端开发.
By targeting haematologic conditions with high unmet medical needs, we aim to deliver innovative medicines and approaches to improve patient outcomes. Our goal is to help transform the lives of patients living with malignant, rare and other related haematologic diseases, shaped by insights from patients, caregivers and physicians to have the most meaningful impact.
AstraZeneca in oncology
澳门在线赌城娱乐正在引领肿瘤学领域的一场革命，致力于为各种形式的癌症提供治疗, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. 正是通过持续的创新，澳门在线赌城娱乐建立了行业中最多样化的产品组合和管道之一, 有可能催化医学实践的变化，改变病人的体验.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
AstraZeneca in BioPharmaceuticals: Respiratory and Immunology
Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key disease area and growth driver to the Company.
澳门在线赌城娱乐是呼吸系统护理领域的领导者，拥有50年的历史，并在免疫介导疾病方面拥有不断增长的药物组合. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. 澳门第一赌城在线娱乐的目标是提供改变生活的药物，帮助消除COPD这一主要死亡原因, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.
With common pathways and underlying disease drivers across respiratory and immunology, 澳门在线赌城娱乐正在跟踪从慢性肺部疾病到免疫驱动疾病领域的科学. 该公司在免疫学领域的业务日益增长，主要集中在五个具有多疾病潜力的中后期特许经营权, in areas including rheumatology (including SLE), dermatology, gastroenterology, and systemic eosinophilic-driven diseases. AstraZeneca’s ambition in Respiratory & 免疫学是实现疾病的改变和持久缓解数以百万计的世界各地的患者.
Forward-looking statements
This announcement may include statements that are not statements of historical fact, or “forward-looking statements,” including with respect to AstraZeneca’s acquisition of Gracell. Such forward-looking statements include, but are not limited to, 澳门在线赌城娱乐的信念和期望以及关于澳门在线赌城娱乐收购Gracell的利益的陈述, the potential effects of the acquisition on AstraZeneca, as well as the expected benefits and success of GC012F and any combination product. 这些陈述基于澳门在线赌城娱乐管理层当前的信念和期望，并受到重大风险和不确定性的影响. 不能保证GC012F或任何其他使用fastcar支持的BCMA/CD19双靶向自体CAR-T细胞疗法的产品将获得必要的监管批准，或者在批准后证明其商业成功. If underlying assumptions prove inaccurate or risks or uncertainties materialise, 实际结果可能与前瞻性陈述中所述的结果有重大差异.
Risks and uncertainties include, but are not limited to, the possibility that the achievement of the specified milestone described in the contingent value rights agreement may take longer to achieve than expected or may never be achieved and the resulting contingent milestone payment may never be realised; general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of COVID-19; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; competition from other products; and challenges inherent in new product development, including obtaining regulatory approval.
AstraZeneca undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. 可能导致结果与前瞻性陈述中描述的结果产生重大差异的其他因素可在截至2023年12月31日的澳门在线赌城娱乐年度报告表格20-F中找到, and Gracell’s Annual Report on Form 20-F for the year ended 31 December 2022, in each case as amended by any subsequent filings made with the SEC. These and other filings made by AstraZeneca and Gracell with the SEC are available at www.sec.gov.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, 澳门在线赌城娱乐在100多个国家开展业务，其创新药物被全球数百万患者使用. Please visit chathams.net and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC